Intertek (CA, USA), a GLP-compliant bioanalytical services provider to the global pharmaceutical industry, has announced its expansion and the relocation of its bioanalytical LC-MS facility in El Dorado Hills, California to Intertek’s existing facility in San Diego.
According to a press release from Intertek, the relocation to the San Diego facility is to be completed by June 2015, and the increased laboratory capacity at the San Diego facility is envisaged to benefit customers involved in preclinical and clinical small molecule drug development. The relocation will be coupled with investment in enhanced MS technology, which will be operational at the new San Diego LC-MS facility prior to relocation in order to circumvent service delivery interruption. In addition, Intertek will be expanding its capability for bioanalytical LC-MS evaluation of biologic drugs, thereby improving its existing large molecule bioanalysis services based at the immunochemistry laboratory in San Diego.
Chetan Parmar, Senior Vice President of Intertek Life Sciences, commented: “Expanding and consolidating our bioanalytical capacity will strengthen our capability to address the challenges our clients encounter during increasingly complex drug development programs and provide them with the right data for informed decision-making”.